Ocular Therapeutix Inc. (OCUL) Stock Price Up 2.7%
Ocular Therapeutix Inc. (NASDAQ:OCUL) shares rose 2.7% on Friday . The company traded as high as $5.03 and last traded at $5.02, with a volume of 225,849 shares changing hands. The stock had previously closed at $4.89.
Several analysts have commented on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $16.00 price objective (down previously from $17.00) on shares of Ocular Therapeutix in a research report on Tuesday, June 7th. Zacks Investment Research lowered shares of Ocular Therapeutix from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. Cowen and Company reaffirmed a “buy” rating on shares of Ocular Therapeutix in a research report on Monday, June 6th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $48.00 price objective on shares of Ocular Therapeutix in a research report on Sunday, April 10th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Ocular Therapeutix currently has an average rating of “Buy” and an average price target of $31.85.
The firm’s market cap is $124.33 million. The stock’s 50 day moving average is $6.50 and its 200-day moving average is $8.53.
Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.43) by $0.01. The firm had revenue of $458 million for the quarter. On average, equities research analysts expect that Ocular Therapeutix Inc. will post ($1.86) EPS for the current year.
In other Ocular Therapeutix news, CEO Amarpreet Sawhney bought 10,000 shares of Ocular Therapeutix stock in a transaction dated Thursday, June 9th. The shares were purchased at an average cost of $6.70 per share, with a total value of $67,000.00. Following the transaction, the chief executive officer now directly owns 573,733 shares of the company’s stock, valued at $3,844,011.10. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.